DONALD W. RICHARDSON, M.D.; ALAN G. ROBINSON, M.D.
Desmopressin (dDAVP), a synthetic analog of the neurohypophyseal nonapeptide arginine vasopressin, has enhanced antidiuretic potency, markedly diminished pressor activity, and a prolonged half-life and duration of action compared to the natural hormone. Desmopressin is the treatment of choice for central diabetes insipidus and can be administered either intranasally or parenterally. A newly approved indication is treatment of mild classical hemophilia and von Willebrand's disease, in which deficient concentrations of factor VIII and von Willebrand's factor are transiently increased to levels that allow minor surgery.
RICHARDSON DW, ROBINSON AG. Drugs Five Years Later: Desmopressin. Ann Intern Med. ;103:228–239. doi: 10.7326/0003-4819-103-2-228
Download citation file:
Published: Ann Intern Med. 1985;103(2):228-239.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use